<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851549</url>
  </required_header>
  <id_info>
    <org_study_id>3178226</org_study_id>
    <nct_id>NCT03851549</nct_id>
  </id_info>
  <brief_title>A User Performance and System Use Evaluation of a New Blood Glucose Monitoring System ( BGMS)</brief_title>
  <official_title>US Regulatory Clinical Evaluation - User Performance and System Use Evaluation of a New Blood Glucose Monitoring System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeScan Scotland Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Diabetes-Technologie ( IfDT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LifeScan Scotland Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the US Regulatory Clinical Evaluation - User Performance and System Use
      Evaluation of a new Blood Glucose Monitoring System (BGMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      User Performance - Assess Lay User fingertip test results obtained on the new BGMS compared
      to a validated method (YSI 2300 STAT PLUS glucose analyzer results) according to FDA Guidance
      2016 section VI.C.

      Assess System Use of the new BGMS, as relevant to self-testing technique, with reference to
      the Owner's Booklet.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 12, 2019</start_date>
  <completion_date type="Anticipated">April 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>User Performance ( UP)</measure>
    <time_frame>&lt; 30 minutes</time_frame>
    <description>User Performance evaluation (referred to as Method Comparison / User Evaluation in FDA Guidance 2016): Lay User accuracy of BGMS by comparison of meter blood glucose results to a laboratory reference instrument.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>System Use Evaluation</measure>
    <time_frame>&lt; 30 minutes</time_frame>
    <description>System usability: Lay user system use evaluation (as relevant to fingertip self-testing) by study personnel observation and completion of a scoring questionnaire.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Blood Glucose monitoring System (BGMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New BGMS (US)</intervention_name>
    <description>New blood glucose monitoring system / In vitro diagnostic device (IVDD)</description>
    <arm_group_label>Blood Glucose monitoring System (BGMS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Summary of inclusion criteria:

        Subject is at least 12 years old. Informed Consent. Subject has a current diagnosis of type
        1 or type 2 diabetes mellitus. Subject reads and understands English. Subject is currently
        performing unassisted self-monitoring of blood glucose (SMBG) OR naive to SMBG for a 10%
        sub-group.

        Summary of exclusion criteria:

        Conflict of interest. Technical expertise.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsty Macleod</last_name>
    <role>Study Director</role>
    <affiliation>LifeScan Scotland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorna Stewart</last_name>
    <phone>+44 01463 721000</phone>
    <email>LSTEWAR5@its.jnj.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Ritchie</last_name>
    <phone>+44 01463 721000</phone>
    <email>lritchi6@its.jnj.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Annnette Baumstark</last_name>
      <email>annette.baumstark@idt-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Barry Irvine</last_name>
      <email>BIRVINE1@its.jnj.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Nina Jendrike</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Barry Irvine</last_name>
      <email>BIRVINE1@its.jnj.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Nicola Zammitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Ritchie</last_name>
      <email>lritchi6@its.jnj.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Srikanth Bellary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Health Science</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle King</last_name>
      <email>dking38@its.jnj.com</email>
    </contact>
    <investigator>
      <last_name>Dr. David Macfarlane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

